EW — Edwards Lifesciences Corporation

Summary of Edwards Lifesciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Sales: $1.57 billion, up 11.6% year-over-year.
• Full Year 2025 Sales Growth: 10.7%.
• Adjusted EPS: $0.58, lower than expected due to increased spending on patient access initiatives.
• GAAP EPS: $0.11, impacted by one-time charges related to the GennaValve acquisition and litigation expenses.
• Adjusted Gross Profit Margin: 78.3%, slightly down from 79% year-over-year.
• SG&A Expenses: $603 million (38% of sales), up from 35% in the prior year due to strategic investments.
• R&D Expenses: $268 million (17.1% of sales), down from 19.6% year-over-year.
• Cash Position: Approximately $3 billion in cash and equivalents, with $2 billion remaining under share repurchase authorization.

2. Strategic Updates and Business Highlights

• TAVR Growth: Q4 global sales of $1.16 billion, up 10.6%, driven by increased focus on the SAPIEN platform and strong clinical data supporting early TAVR treatment.
• TMTT Growth: Sales grew over 40% to $156 million, with expectations to reach $2 billion by 2030, fueled by new product launches like SAPIEN M3 and NextGen PASCAL.
• Surgical Product Group: Q4 sales of $254 million, up 2%, with full-year sales exceeding $1 billion for the first time.
• Partnerships: Expanded partnership with the American Heart Association to improve heart valve disease management.
• Guideline Changes: New European guidelines promoting earlier treatment for severe aortic stenosis are expected to boost TAVR adoption.

3. Forward Guidance and Outlook

• 2026 Sales Growth Guidance: 8% to 10%.
• EPS Guidance for 2026: $2.90 to $3.05.
• Q1 2026 Sales Guidance: $1.55 billion to $1.63 billion, with expected higher growth rates in the first half of the year.
• Long-term Growth: Anticipated average annual sales growth of 10% with operating margin expansion through 2027 and beyond.

4. Bad News, Challenges, or Points of Concern

• Increased Spending: Higher-than-expected SG&A expenses due to aggressive investments in patient access initiatives, which may pressure margins in the short term.
• Tax Rate: Reported tax rate was 29%, higher than anticipated, impacting earnings.
• Competitive Pressures: While TAVR growth is strong, the company faces competition and market dynamics, particularly following competitor exits.
• Regulatory Risks: Uncertainty surrounding the upcoming national coverage determination (NCD) for TAVR could impact future growth.

5. Notable Q&A Insights

• TAVR Market Dynamics: Management confirmed that TAVR growth is partly due to share gains following competitor exits, with a stable competitive position globally.
• Patient Access Initiatives: Increased spending in Q4 was strategic, aimed at amplifying patient access and education, particularly around asymptomatic TAVR.
• Lifetime Management: Discussion highlighted the importance of lifetime management for TAVR patients, emphasizing the need for effective first procedures to ensure future treatment options.
• Moderate AS Opportunity: Management expressed confidence in the potential of moderate aortic stenosis treatments but emphasized the need for robust clinical evidence before making definitive market claims.

Overall, Edwards Lifesciences demonstrated strong financial performance in Q4 2025, with strategic initiatives aimed at expanding its market presence and addressing patient needs. However, increased spending and regulatory uncertainties present challenges that the company will need to navigate in the coming year.